CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
CT38drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03613129
NCT03613129Phase 2Completed
CompareCT.gov

Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

LUCINDA BATEMAN, MD·interventional·Posted Aug 2, 2018·Updated May 12, 2020

In Brief

A Phase 2 clinical trial evaluating CT38 for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This study seeks to investigate the safety, tolerability and efficacy of CT38, an experimental peptide administered by subcutaneous infusion, in the treatment of ME/CFS patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyalgic Encephalomyelitis, Chronic Fatigue Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2, 2018
Enrollment StartJul 23, 2018
Primary CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.9 years ago

Interventions

CT38drug

Infusion